IP Library › Granted Patent US 8,431,540
Granted Patent B2
US 8,431,540 · App. 13/234,956 · Granted Apr 30, 2013

Modified lysine-mimetic compounds

Inventors: Bjarne Due Larsen (Roskilde, DK); Jørgen Søberg Petersen (Hellebæk, DK); Ketil Jørgen Haugan (Slangerup, DK); John A. Butera (Clarksburg, NJ); James K. Hennan (Harleysville, PA); Edward H. Kerns (Skillman, NJ); Evgueni Lvovich Piatnitski (Conshohocken, PA)
Assignee: Zealand Pharma A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,431,540
App. No.
13/234,956
Granted
Apr 30, 2013
Kind
B2
Abstract

Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.

Claims (16)

1. A method of treating ischemia, or ischemic injury in the organs of a mammal, comprising administering to a subject a therapeutically effective amount of a compound that is

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , for treating acute ischemic heart disease.

3. The method according to claim 1 , for treating stable or unstable angina pectoris.

4. The method according to claim 1 , for treating acute myocardial infarction.

5. The method according to claim 1 , for treating ischemic injury in the gastrointestinal tract.

6. The method according to claim 1 , wherein the subject is a human being.

7. The method according to claim 1 , wherein the compound is formulated for parenteral or oral administration.

8. A method of treating ischemia, or ischemic injury in the organs of a mammal, comprising administering to a subject a therapeutically effective amount of a compound that is

or a pharmaceutically acceptable salt thereof.

9. The method according to claim 8 , for treating acute ischemic heart disease.

10. The method according to claim 8 , for treating stable or unstable angina pectoris.

11. The method according to claim 8 , for treating acute myocardial infarction.

12. The method according to claim 8 , for treating ischemic injury in the gastrointestinal tract.

13. The method according to claim 8 , wherein the subject is a human being.

14. The method according to claim 8 , wherein the compound is formulated for parenteral or oral administration.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 11, 2023
From: ZOOLANDER SA LLC
To: ZEALAND PHARMA A/S
Reel/Frame 063624/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2015
From: LARSEN, BJARNE DUE; PETERSEN, JØRGEN SØBERG; HAUGAN, KETIL JØRGEN; BUTERA, JOHN A.; HENNAN, JAMES K.; KERNS, EDWARD H.; CHEKLER, EUGENE LVOVICH PIATNITSKI
To: ZEALAND PHARMA A/S; WYETH LLC
Reel/Frame 036705/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2015
From: WYETH LLC
To: ZEALAND PHARMA A/S
Reel/Frame 036706/0100 →
Continuity (4)
Continuation 12610172 · Oct 30, 2009
Division 11643192 · Dec 21, 2006
Provisional Application 60753628 · Dec 23, 2005
Related Publication 20120245106A1 · Sep 27, 2012